Show simple item record

dc.contributor.authorCamidge, R
dc.contributor.authorKim, H
dc.contributor.authorAhn, M
dc.contributor.authorYang, J
dc.contributor.authorHan, J
dc.contributor.authorLee, J
dc.contributor.authorHochmair, M
dc.contributor.authorLi, J
dc.contributor.authorChang, G
dc.contributor.authorLee, K
dc.contributor.authorGridelli, C
dc.contributor.authorDelmonte, A
dc.contributor.authorCampelo, M
dc.contributor.authorKim, D
dc.contributor.authorBearz, A
dc.contributor.authorGriesinger, F
dc.contributor.authorMorabito, A
dc.contributor.authorFelip, E
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorGhosh, S
dc.contributor.authorSpira, A
dc.contributor.authorGettinger, S
dc.contributor.authorTiseo, M
dc.contributor.authorHaney, J
dc.contributor.authorKerstein, D
dc.contributor.authorPopat, S
dc.date.accessioned2019-02-08T15:20:07Z
dc.date.available2019-02-08T15:20:07Z
dc.date.issued2018en
dc.identifier.citationCamidge R, Kim HR, Ahn M, Yang JC, Han J, Lee J, et al. PL02.03 Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)). J Thorac Oncol. 2018;13(10):S184-S185.en
dc.identifier.doi10.1016/j.jtho.2018.08.011en
dc.identifier.urihttp://hdl.handle.net/10541/621511
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2018.08.011en
dc.titleBrigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Colorado Cancer Center, Aurora, CO/USen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record